Trastuzumab and other novel therapies in breast cancer

Handbook of Metastatic Breast Cancer

Volumn , Issue , 2006, Pages 61-78

  Jones, Robin L ^a   Smith, Ian E ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955742198     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (74)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
3. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
5. Barnes DM, Bartkova J, Camplejohn RS, et al. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 1992; 28: 644-8.
6. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16: 413-28.
7. Hudziak RM, Lewis GD, Winget M, et al. p185 HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumour cells to tumour necrosis factor. Mol Cell Biol 1989; 9: 1165-72.
8. Fendly BM, Winget M, Hudziak RM, et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990; 50: 1550-8.
9. Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 9: 1829-38.
10. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18: 3651-64.
11. Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002; 20: 3095-105.
12. Bilous M. Predicting HER2 status of breast cancer from basic pathology features: HER2 status of 1500 breast cancers determined by immunohistochemistry and fluorescence in situ hybridisation with pathology correlation. Eur J Cancer 2002; 38: S52.
13. Persons DL, Bui MM, Lowery MC, et al. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter probability study. Ann Clin Lab Sci 2000; 30: 41-8.
14. Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridisation and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005; 93(1): 3-11.
15. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
16. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project Experience. J Natl Cancer Inst 2002; 94: 852-4.
17. Fornier M, Risio M, van Poznak C, et al. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Williston Park) 2002; 16: 1340-8.
18. Sun JM, Han W, Im SA, et al. A combination of HER-2 status and the St. Gallen classification provides useful information in lymph node-negative breast carcinoma. Cancer 2004; 101: 2516-22.
19. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridisation: a practical alternative for fluorescence in situ hybridisation to detect HER2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000; 157: 1467-72.
20. Madrid MA, Lo RW. Chromogenic in situ hybridisation (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status. Breast Cancer Res 2004; 6: R593-600.
21. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized Anti-HER2 monoclonal antibody in women who have HER2- overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48.
22. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18: 2241-51.
23. Konecny G, Pegram MD, Beryt M, et al. Therapeutic advantage of chemotherapy drugs in combination with herceptin against human breast cancer cells with HER-2/neu overexpression. Breast Cancer Res Treat 1999; 57: 114; Abstract 467.
24. r-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002; 49: 211-16.
25. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
26. Marty M, Cognetti F, Maraninchi D, et al. Randomised phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-74.
27. Jones RL, Smith IE. Efficacy and safety of trastuzumab. Expert Opin Drug Saf 2004; 314: 317-27.
28. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 1800-8.
29. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-30.
30. Pegram MD, Pienkowski T, Northfield DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96: 759-69.
31. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91(4): 639-43.
32. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97(12): 2972-7.
33. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22(6): 1063-70.
34. Fountzilas G, Razis E, Tsavdaridis D, et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer 2003; 4(2): 120-5.
35. Gelmon KA, Mackey J, Verma S, et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 2004; 5(1): 52-8.
36. Meng S, Tripathy D, Shete S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004; 101(25): 9393-8.
37. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
38. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
39. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003; 21: 46-53.
40. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathological complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-85.
41. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-21.
42. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy in breast cancer. Endocr Relat Cancer 2001; 8: 191-5.
43. Lipton A, Ali SM, Leitzel K, et al. Elevated HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002; 20: 1467-72.
44. de Laurentiis M, Arpino G, Massarelli E, et al. HER2 as a predictive marker of resistance to endocrine treatment (ET) for advanced breast cancer (ABC): a meta-analysis of published studies. Breast Cancer Res Treat 2002; 70: S68, Abstract 233.
45. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1- and/or erb-B-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-16.
46. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicentre doubleblind randomized trial. J Clin Oncol 2005; 23: 5108-16.
47. Lipton A, Ali SM, Leitzel K, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003; 21: 1967-72.
48. Johnston SR. Combinations of endocrine and biological agents: present status of therapeutic and presurgical intervention. Clin Cancer Res 2005; 11: 889s-99s.
49. Osborne CK, Bardou V, Torsten A, et al. Role of the oestrogen receptor coactivator A1B1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95: 353-61.
50. Burris HA, Taylor C, Jones S, et al. A phase I study of GW572016 in patients with solid tumours. Proc Am Soc Clin Oncol 2003; 22: 258, Abstract 994.
51. Spector N, Xia W, Burris H 3rd, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumour growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23: 2502-12.
52. Blackwell KL, Burstein H, Pegram M, et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. Proc Am Soc Clin Oncol 2005; 24: Abstract 3004.
53. Gomez HL, Chavez MA, Doval DC, et al. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 2005; 24: Abstract 3046.
54. Albain K, Elledge R, Gradishar W, et al. Open-label, phase II, multicenter trial of ZD1839 (“Iressa”) in patients with advanced breast cancer. Breast Cancer Res Treat 2002; 76: S33, Abstract 20.
55. Winer E, Cobleigh M, Dickler M, et al. Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2002; 76: S115, Abstract 445.
56. Robertson JFR, Gutteridge E, Cheung KL, et al. Gefitinib (ZD1839) is active in acquired tamoxifen-resistant oestrogen receptor positive and ER-negative breast cancer: results from a phase II study. Proc Am Soc Clin Oncol 2003; 22: Abstract 23.
57. Baselga J, Albanelli J, Riuz A, et al. Phase II and tumour pharmacodynamic study of gefi-tinib in patients with advanced breast cancer. Proc Am Soc Clin Oncol 2003; 22: Abstract 24.
58. McCormack F. Activators and effectors of ras p21 proteins. Curr Opin Genet Dev 1994; 4: 71-6.
59. Clark GJ, Der CJ. Ras proto-oncogene activation in human malignancy. In: Markers CT, Garret T, Sell S, eds. Cellular Cancer. Totowa, NJ: Humana Press, 1995: 17-52.
60. Clark GJ, Der CJ. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 1995; 35: 133-44.
61. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999; 17: 3631-52.
62. Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777 in advanced breast cancer. J Clin Oncol 2003; 21: 2492-9.
63. Johnston SR, Semiglazov V, Manikhas G, et al. A randomised, blinded, phase II study of tipifarnib (Zarnestra) combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat 2005; 94, Abstract 5087.
64. Chen J, Fang Y. A novel pathway regulating the mammalian target of rapamycin (mTOR) signalling. Biochem Pharmacol 2002; 64: 1071-7.
65. Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a the rapeutic target against cancer. Cancer Biol Ther 2003; 2: S169-77.
66. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumour agents: from bench to clinic. Curr Opin Investig Drugs 2002; 3: 295-304.
67. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer; the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249-58.
68. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23: 5314-22.
69. Baselga J, Fumoleau P, Gil M, et al. Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. Proc Am Soc Clin Oncol 2004; 22: 14S, Abstract 544.
70. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term data. J Clin Oncol 2001; 19: 851-6.
71. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of beva-cizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30: 117-24.
72. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-50.
73. Miller KD, Chap LI, Holmes FA, et al. Randomized phase II trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-9.
74. Miller KD, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005; 94; Abstract 3.